Formycon AG (XTER:FYB) ROCE % : 16.96% (As of Dec. 2023)

View and export this data going back to 2010. Start your Free Trial

What is Formycon AG ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Formycon AG's annualized ROCE % for the quarter that ended in Dec. 2023 was 16.96%.

Formycon AG ROCE % Historical Data

The historical data trend for Formycon AG's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Formycon AG ROCE % Chart

Formycon AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-5.24

-10.88

-21.36

8.49

9.75

Formycon AG Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial															-11.83	37.05	-10.81	2.23	16.96

Formycon AG ROCE % Calculation

Formycon AG's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	79.15	/	( ( (853.697 - 50.667)	+	(890.362 - 69.305) )	/ 2 )
	=	79.15	/	( (803.03	+	821.057)	/ 2 )
	=	79.15	/	812.0435
	=	9.75 %

Formycon AG's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	140.096	/	( ( (912.944 - 82.086)	+	(890.362 - 69.305) )	/ 2 )
	=	140.096	/	( ( 830.858	+	821.057 )	/ 2 )
	=	140.096	/	825.9575
	=	16.96 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

Formycon AG (XTER:FYB) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Formycon AG ROCE % Related Terms

Thank you for viewing the detailed overview of Formycon AG's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Formycon AG (XTER:FYB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Formycon AG (XTER:FYB) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

FYB:Germany FYB:Germany FYB:Germany

Address

Fraunhoferstrasse 15, Martinsried, Planegg, BY, DEU, 82152

Website

https://www.formycon.com

Formycon AG is a pharmaceutical company. It is engaged in the development of pharmaceutical and biopharmaceutical products and the development of drug delivery systems. Its focus is on treatments in ophthalmology and immunology as well as other chronic diseases. The company's pipeline in the biosimilar drugs category includes FYB201, FYB202, FYB203, and FYB207 for the treatment of COVID 19. It is also engaged in the provision of diagnostic laboratory services and works for third parties and the carrying out of diagnostic laboratory services.

Executives

Dr. Stefan Glombitza	Board of Directors
Dr. Carsten Brockmeyer	Board of Directors
Dr. Nicolas Combé	Board of Directors

Formycon AG (XTER:FYB) Headlines

No Headlines